<span item_type="fundamental" item_id="6fb041a70b3093c9795ea14d971f437a" counter_id="ST/US/BCLI" env="prod"></span><span item_type="announcement" item_id="516480250020895105" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.45, beating the estimate of USD -0.97.</p><p></p><h3>Cash and Cash Equivalents</h3><p>Cash, cash equivalents, and restricted cash were approximately $1.8 million as of March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_ex99-1.htm"></span></p><h3>Research and Development Expenditures</h3><p>Research and development expenditures, net, for the quarter ended March 31, 2025, were $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_ex99-1.htm"></span></p><h3>General and Administrative Expenses</h3><p>General and administrative expenses for the quarter ended March 31, 2025, were approximately $1.8 million, compared to approximately $1.5 million for the quarter ended March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_ex99-1.htm"></span></p><h3>Net Loss</h3><p>Net loss for the quarter ended March 31, 2025, was approximately $2.9 million, as compared to a net loss of approximately $3.4 million for the quarter ended March 31, 2024. Net loss per share for the three months ended March 31, 2025, and 2024 was $0.45 and $0.75, respectively.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_ex99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>BrainStorm Cell Therapeutics is focused on advancing its NurOwn® development program, with plans to initiate a Phase 3b trial to confirm the product’s efficacy in early-stage ALS patients and support a new BLA submission. The company has submitted an IND amendment to the FDA and is finalizing clinical trial agreements with leading academic centers. BrainStorm believes that NurOwn, if approved, has the potential to become a valuable treatment option for ALS patients.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_ex99-1.htm"></span></p>

Brainstorm Cell | 8-K: FY2025 Q1 EPS Beats Estimate at USD -0.45